Illinois General Assembly - Full Text of HB0813
Illinois General Assembly

Previous General Assemblies

Full Text of HB0813  95th General Assembly

HB0813eng 95TH GENERAL ASSEMBLY



 


 
HB0813 Engrossed LRB095 09713 DRJ 29917 b

1     AN ACT concerning health.
 
2     Be it enacted by the People of the State of Illinois,
3 represented in the General Assembly:
 
4     Section 1. Short title. This Act may be cited as the Cancer
5 Drug Repository Program Act.
 
6     Section 5. Definitions. In this Act:
7     "Cancer drug" means a prescription drug that is used to
8 treat any of the following:
9         (1) Cancer or side effects of cancer.
10         (2) The side effects of any prescription drug that is
11     used to treat cancer or side effects of cancer.
12     "Department" means the Department of Public Health.
13     "Dispense" has the meaning given to that term in the
14 Pharmacy Practice Act of 1987.
15     "Pharmacist" means an individual licensed to engage in the
16 practice of pharmacy under the Pharmacy Practice Act of 1987.
17     "Pharmacy" means a pharmacy registered in this State under
18 the Pharmacy Practice Act of 1987.
19     "Practitioner" means a person licensed in this State to
20 prescribe and administer drugs or licensed in another state and
21 recognized by this State as a person authorized to prescribe
22 and administer drugs.
23     "Prescription drug" means any prescribed drug that may be

 

 

HB0813 Engrossed - 2 - LRB095 09713 DRJ 29917 b

1 legally dispensed by a pharmacy.
2     "Program" means the cancer drug repository program
3 established under this Act.
 
4     Section 10. Cancer drug repository program. The Department
5 shall establish and maintain a cancer drug repository program,
6 under which any person may donate a cancer drug or supplies
7 needed to administer a cancer drug for use by an individual who
8 meets eligibility criteria specified by the Department in
9 rules. Donations may be made on the premises of a pharmacy that
10 elects to participate in the program and meets requirements
11 specified by the Department in rules. The pharmacy may charge
12 an individual who receives a cancer drug or supplies needed to
13 administer a cancer drug under this Act a handling fee that may
14 not exceed the amount specified by the Department in rules. A
15 pharmacy that receives a donated cancer drug or supplies needed
16 to administer a cancer drug under this Act may distribute the
17 cancer drug or supplies to another eligible pharmacy for use
18 under the program.
 
19     Section 15. Requirements for accepting and dispensing
20 cancer drugs and supplies. A cancer drug or supplies needed to
21 administer a cancer drug may be accepted and dispensed under
22 the program only if all of the following requirements are met:
23         (1) The cancer drug or supplies needed to administer a
24     cancer drug are in their original, unopened, sealed, and

 

 

HB0813 Engrossed - 3 - LRB095 09713 DRJ 29917 b

1     tamper-evident unit-dose packaging or, if packaged in
2     single-unit doses, the single-unit-dose packaging is
3     unopened.
4         (2) The cancer drug bears an expiration date that is
5     later than 6 months after the date that the drug was
6     donated.
7         (3) The cancer drug or supplies needed to administer a
8     cancer drug are not adulterated or misbranded, as
9     determined by a pharmacist employed by, or under contract
10     with, the pharmacy where the drug or supplies are accepted
11     or dispensed. The pharmacist must inspect the drug or
12     supplies before the drug or supplies are dispensed.
13         (4) The cancer drug or supplies needed to administer a
14     cancer drug are prescribed by a practitioner for use by an
15     eligible individual.
 
16     Section 20. Resale of donated drugs or supplies prohibited.
17 No cancer drug or supplies needed to administer a cancer drug
18 that are donated for use under this Act may be resold.
 
19     Section 25. Participation in program not required. Nothing
20 in this Act requires that a pharmacy or pharmacist participate
21 in the cancer drug repository program.
 
22     Section 30. Immunity.
23     (a) Unless the manufacturer's conduct is wilful and wanton,

 

 

HB0813 Engrossed - 4 - LRB095 09713 DRJ 29917 b

1 a manufacturer of a drug or supply is not subject to criminal
2 or civil liability for injury, death, or loss to a person or
3 property for matters related to the donation, acceptance, or
4 dispensing of a cancer drug or supply manufactured by the
5 manufacturer that is donated by any person under this Act.
6     (b) Unless the person's conduct is wilful and wanton, a
7 person is immune from civil liability for injury to or the
8 death of the individual to whom the cancer drug or supply is
9 dispensed and may not be found guilty of unprofessional conduct
10 for his or her acts or omissions related to donating,
11 accepting, distributing, or dispensing a cancer drug or supply
12 under this Act.
 
13     Section 35. Rules. The Department shall adopt all of the
14 following as rules:
15         (1) Requirements for pharmacies to accept and dispense
16     donated cancer drugs or supplies needed to administer
17     cancer drugs under this Act, including all of the
18     following:
19             (A) Eligibility criteria.
20             (B) Standards and procedures for accepting, safely
21         storing, and dispensing donated cancer drugs or
22         supplies needed to administer cancer drugs.
23             (C) Standards and procedures for inspecting
24         donated cancer drugs or supplies needed to administer
25         cancer drugs to determine whether the drugs or supplies

 

 

HB0813 Engrossed - 5 - LRB095 09713 DRJ 29917 b

1         are in their original, unopened, sealed, and
2         tamper-evident unit-dose packaging or, if packaged in
3         single-unit doses, the single-unit-dose packaging is
4         unopened.
5             (D) Standards and procedures for inspecting
6         donated cancer drugs or supplies needed to administer
7         cancer drugs to determine that the drugs or supplies
8         needed to administer cancer drugs are not adulterated
9         or misbranded.
10         (2) Eligibility criteria for individuals to receive
11     donated cancer drugs or supplies needed to administer
12     cancer drugs dispensed under the cancer drug repository
13     program. The standards shall prioritize dispensation to
14     individuals who are uninsured or indigent but must permit
15     dispensation to others if an uninsured or indigent
16     individual is unavailable.
17         (3) A means, such as an identification card, by which
18     an individual who is eligible to receive a donated cancer
19     drug or supplies needed to administer a cancer drug may
20     indicate that eligibility.
21         (4) Necessary forms for administration of the cancer
22     drug repository program, including forms for use by persons
23     that donate, accept, distribute, or dispense cancer drugs
24     or supplies needed to administer cancer drugs under the
25     program.
26         (5) The maximum handling fee that a pharmacy may charge

 

 

HB0813 Engrossed - 6 - LRB095 09713 DRJ 29917 b

1     for accepting, distributing, or dispensing donated cancer
2     drugs or supplies needed to administer cancer drugs.
3         (6) A list of cancer drugs and supplies needed to
4     administer cancer drugs, arranged by category or by
5     individual cancer drug or supply, that the cancer drug
6     repository program will accept for dispensing.
7         (7) A list of cancer drugs and supplies needed to
8     administer cancer drugs, arranged by category or by
9     individual cancer drug or supply, that the cancer drug
10     repository program will not accept for dispensing. The list
11     must include a statement that specifies the reason that the
12     drug or supplies are ineligible for donation.
13     The Department may also adopt any other rules deemed
14 necessary to implement this Act.
 
15     Section 90. The Pharmacy Practice Act of 1987 is amended by
16 changing Section 4 as follows:
 
17     (225 ILCS 85/4)  (from Ch. 111, par. 4124)
18     (Section scheduled to be repealed on January 1, 2008)
19     Sec. 4. Exemptions. Nothing contained in any Section of
20 this Act shall apply to, or in any manner interfere with:
21     (a) the lawful practice of any physician licensed to
22 practice medicine in all of its branches, dentist, podiatrist,
23 veterinarian, or therapeutically or diagnostically certified
24 optometrist within the limits of his or her license, or prevent

 

 

HB0813 Engrossed - 7 - LRB095 09713 DRJ 29917 b

1 him or her from supplying to his or her bona fide patients such
2 drugs, medicines, or poisons as may seem to him appropriate;
3     (b) the sale of compressed gases;
4     (c) the sale of patent or proprietary medicines and
5 household remedies when sold in original and unbroken packages
6 only, if such patent or proprietary medicines and household
7 remedies be properly and adequately labeled as to content and
8 usage and generally considered and accepted as harmless and
9 nonpoisonous when used according to the directions on the
10 label, and also do not contain opium or coca leaves, or any
11 compound, salt or derivative thereof, or any drug which,
12 according to the latest editions of the following authoritative
13 pharmaceutical treatises and standards, namely, The United
14 States Pharmacopoeia/National Formulary (USP/NF), the United
15 States Dispensatory, and the Accepted Dental Remedies of the
16 Council of Dental Therapeutics of the American Dental
17 Association or any or either of them, in use on the effective
18 date of this Act, or according to the existing provisions of
19 the Federal Food, Drug, and Cosmetic Act and Regulations of the
20 Department of Health and Human Services, Food and Drug
21 Administration, promulgated thereunder now in effect, is
22 designated, described or considered as a narcotic, hypnotic,
23 habit forming, dangerous, or poisonous drug;
24     (d) the sale of poultry and livestock remedies in original
25 and unbroken packages only, labeled for poultry and livestock
26 medication;

 

 

HB0813 Engrossed - 8 - LRB095 09713 DRJ 29917 b

1     (e) the sale of poisonous substances or mixture of
2 poisonous substances, in unbroken packages, for nonmedicinal
3 use in the arts or industries or for insecticide purposes;
4 provided, they are properly and adequately labeled as to
5 content and such nonmedicinal usage, in conformity with the
6 provisions of all applicable federal, state and local laws and
7 regulations promulgated thereunder now in effect relating
8 thereto and governing the same, and those which are required
9 under such applicable laws and regulations to be labeled with
10 the word "Poison", are also labeled with the word "Poison"
11 printed thereon in prominent type and the name of a readily
12 obtainable antidote with directions for its administration;
13     (f) the delegation of limited prescriptive authority by a
14 physician licensed to practice medicine in all its branches to
15 a physician assistant under Section 7.5 of the Physician
16 Assistant Practice Act of 1987. This delegated authority may
17 but is not required to include prescription of Schedule III,
18 IV, or V controlled substances, as defined in Article II of the
19 Illinois Controlled Substances Act, in accordance with written
20 guidelines under Section 7.5 of the Physician Assistant
21 Practice Act of 1987; and
22     (g) the The delegation of limited prescriptive authority by
23 a physician licensed to practice medicine in all its branches
24 to an advanced practice nurse in accordance with a written
25 collaborative agreement under Sections 15-15 and 15-20 of the
26 Nursing and Advanced Practice Nursing Act. This delegated

 

 

HB0813 Engrossed - 9 - LRB095 09713 DRJ 29917 b

1 authority may but is not required to include the prescription
2 of Schedule III, IV, or V controlled substances as defined in
3 Article II of the Illinois Controlled Substances Act; and .
4     (h) the donation or acceptance, or the packaging,
5 repackaging, or labeling, of prescription drugs to the extent
6 permitted or required under the Cancer Drug Repository Program
7 Act.
8 (Source: P.A. 90-116, eff. 7-14-97; 90-253, eff. 7-29-97;
9 90-655, eff. 7-30-98; 90-742, eff. 8-13-98.)
 
10     Section 91. The Wholesale Drug Distribution Licensing Act
11 is amended by changing Section 15 as follows:
 
12     (225 ILCS 120/15)  (from Ch. 111, par. 8301-15)
13     (Section scheduled to be repealed on January 1, 2013)
14     Sec. 15. Definitions. As used in this Act:
15     "Blood" means whole blood collected from a single donor and
16 processed either for transfusion or further manufacturing.
17     "Blood component" means that part of blood separated by
18 physical or mechanical means.
19     "Board" means the State Board of Pharmacy of the Department
20 of Professional Regulation.
21     "Department" means the Department of Professional
22 Regulation.
23     "Director" means the Director of Professional Regulation.
24     "Drug sample" means a unit of a prescription drug that is

 

 

HB0813 Engrossed - 10 - LRB095 09713 DRJ 29917 b

1 not intended to be sold and is intended to promote the sale of
2 the drug.
3     "Manufacturer" means anyone who is engaged in the
4 manufacturing, preparing, propagating, compounding,
5 processing, packaging, repackaging, or labeling of a
6 prescription drug. "Manufacturer" does not include anyone who
7 is engaged in the packaging, repackaging, or labeling of
8 prescription drugs only to the extent required under the Cancer
9 Drug Repository Program Act.
10     "Person" means and includes a natural person, partnership,
11 association or corporation.
12     "Pharmacy distributor" means any pharmacy licensed in this
13 State or hospital pharmacy that is engaged in the delivery or
14 distribution of prescription drugs either to any other pharmacy
15 licensed in this State or to any other person or entity
16 including, but not limited to, a wholesale drug distributor
17 engaged in the delivery or distribution of prescription drugs
18 who is involved in the actual, constructive, or attempted
19 transfer of a drug in this State to other than the ultimate
20 consumer except as otherwise provided for by law.
21     "Prescription drug" means any human drug required by
22 federal law or regulation to be dispensed only by a
23 prescription, including finished dosage forms and active
24 ingredients subject to subsection (b) of Section 503 of the
25 Federal Food, Drug and Cosmetic Act.
26     "Wholesale distribution" or "wholesale distributions"

 

 

HB0813 Engrossed - 11 - LRB095 09713 DRJ 29917 b

1 means distribution of prescription drugs to persons other than
2 a consumer or patient, but does not include any of the
3 following:
4         (a) Intracompany sales, defined as any transaction or
5     transfer between any division, subsidiary, parent, or
6     affiliated or related company under the common ownership
7     and control of a corporate entity.
8         (b) The purchase or other acquisition by a hospital or
9     other health care entity that is a member of a group
10     purchasing organization of a drug for its own use from the
11     group purchasing organization or from other hospitals or
12     health care entities that are members of a group
13     organization.
14         (c) The sale, purchase, or trade of a drug or an offer
15     to sell, purchase, or trade a drug by a charitable
16     organization described in subsection (c)(3) of Section 501
17     of the U.S. Internal Revenue Code of 1954 to a nonprofit
18     affiliate of the organization to the extent otherwise
19     permitted by law.
20         (d) The sale, purchase, or trade of a drug or an offer
21     to sell, purchase, or trade a drug among hospitals or other
22     health care entities that are under common control. For
23     purposes of this Act, "common control" means the power to
24     direct or cause the direction of the management and
25     policies of a person or an organization, whether by
26     ownership of stock, voting rights, contract, or otherwise.

 

 

HB0813 Engrossed - 12 - LRB095 09713 DRJ 29917 b

1         (e) The sale, purchase, or trade of a drug or an offer
2     to sell, purchase, or trade a drug for emergency medical
3     reasons. For purposes of this Act, "emergency medical
4     reasons" include transfers of prescription drugs by a
5     retail pharmacy to another retail pharmacy to alleviate a
6     temporary shortage.
7         (f) The sale, purchase, or trade of a drug, an offer to
8     sell, purchase, or trade a drug, or the dispensing of a
9     drug pursuant to a prescription.
10         (g) The distribution of drug samples by manufacturers'
11     representatives or distributors' representatives.
12         (h) The sale, purchase, or trade of blood and blood
13     components intended for transfusion.
14         (i) The donation of prescription drugs to the extent
15     permitted under the Cancer Drug Repository Program Act.
16     "Wholesale drug distributor" means any person or entity
17 engaged in wholesale distribution of prescription drugs,
18 including, but not limited to, manufacturers; repackers; own
19 label distributors; jobbers; private label distributors;
20 brokers; warehouses, including manufacturers' and
21 distributors' warehouses, chain drug warehouses, and wholesale
22 drug warehouses; independent wholesale drug traders; and
23 retail pharmacies that conduct wholesale distributions,
24 including, but not limited to, any pharmacy distributor as
25 defined in this Section. A wholesale drug distributor shall not
26 include any for hire carrier or person or entity hired solely

 

 

HB0813 Engrossed - 13 - LRB095 09713 DRJ 29917 b

1 to transport prescription drugs.
2 (Source: P.A. 87-594.)
 
3     Section 92. The Senior Pharmaceutical Assistance Act is
4 amended by changing Section 10 as follows:
 
5     (320 ILCS 50/10)
6     Sec. 10. Definitions. In this Act:
7     "Manufacturer" includes:
8         (1) An entity that is engaged in (a) the production,
9     preparation, propagation, compounding, conversion, or
10     processing of prescription drug products (i) directly or
11     indirectly by extraction from substances of natural
12     origin, (ii) independently by means of chemical synthesis,
13     or (iii) by combination of extraction and chemical
14     synthesis; or (b) the packaging, repackaging, labeling or
15     re-labeling, or distribution of prescription drug
16     products.
17         (2) The entity holding legal title to or possession of
18     the national drug code number for the covered prescription
19     drug.
20     The term does not include a wholesale distributor of drugs,
21 drugstore chain organization, or retail pharmacy licensed by
22 the State. The term also does not include anyone who is engaged
23 in the packaging, repackaging, or labeling of prescription
24 drugs only to the extent required under the Cancer Drug

 

 

HB0813 Engrossed - 14 - LRB095 09713 DRJ 29917 b

1 Repository Program Act.
2     "Prescription drug" means a drug that may be dispensed only
3 upon prescription by an authorized prescriber and that is
4 approved for safety and effectiveness as a prescription drug
5 under Section 505 or 507 of the Federal Food, Drug and Cosmetic
6 Act.
7     "Senior citizen" or "senior" means a person 65 years of age
8 or older.
9 (Source: P.A. 92-594, eff. 6-27-02.)
 
10     Section 93. The Illinois Food, Drug and Cosmetic Act is
11 amended by changing Section 16 as follows:
 
12     (410 ILCS 620/16)  (from Ch. 56 1/2, par. 516)
13     Sec. 16. (a) The Director is hereby authorized to
14 promulgate regulations exempting from any labeling or
15 packaging requirement of this Act drugs and devices which are
16 (i) , in accordance with the practice of the trade, to be
17 processed, labeled or repacked in substantial quantities at
18 establishments other than those where originally processed or
19 packaged on condition that such drugs and devices are not
20 adulterated or misbranded under the provisions of this Act upon
21 removal from such processing, labeling or repacking
22 establishment or (ii) packaged, repackaged, or labeled to the
23 extent required under the Cancer Drug Repository Program Act.
24     (b) Drugs and device labeling or packaging exemptions

 

 

HB0813 Engrossed - 15 - LRB095 09713 DRJ 29917 b

1 adopted under the Federal Act and supplements thereto or
2 revisions thereof shall apply to drugs and devices in Illinois
3 except insofar as modified or rejected by regulations
4 promulgated by the Director.
5     (c) A drug intended for use by man which (A) is a
6 habit-forming drug to which Section 15 (d) applies; or (B)
7 because of its toxicity or other potentiality for harmful
8 effect or the method of its use or the collateral measures
9 necessary to its use is not safe for use except under the
10 supervision of a practitioner licensed by law to administer
11 such drug; or (C) is limited by an approved application under
12 Section 505 of the Federal Act or Section 17 of this Act to use
13 under the professional supervision of a practitioner licensed
14 by law to administer such drug, shall be dispensed only in
15 accordance with the provisions of the "Illinois Controlled
16 Substances Act". The act of dispensing a drug contrary to the
17 provisions of this paragraph shall be deemed to be an act which
18 results in a drug being misbranded while held for sale.
19     (d) Any drug dispensed by filling or refilling a written or
20 oral prescription of a practitioner licensed by law to
21 administer such drug shall be exempt from the requirements of
22 Section 15, except subsections (a), (k) and (l) and clauses (2)
23 and (3) of subsection (i), and the packaging requirements of
24 subsections (g), (h) and (q), if the drug bears a label
25 containing the proprietary name or names, or if there is none,
26 the established name or names of the drugs, the dosage and

 

 

HB0813 Engrossed - 16 - LRB095 09713 DRJ 29917 b

1 quantity, unless the prescribing practitioner, in the interest
2 of the health of the patient, directs otherwise in writing, the
3 name and address of the dispenser, the serial number and date
4 of the prescription or of its filling, the name of the
5 prescriber and, if stated in the prescription, the name of the
6 patient, and the directions for use and the cautionary
7 statements, if any, contained in such prescription. This
8 exemption shall not apply to any drug dispensed in the course
9 of the conduct of business of dispensing drugs pursuant to
10 diagnosis by mail, or to a drug dispensed in violation of
11 subsection (a) of this Section.
12     (e) The Director may by regulation remove drugs subject to
13 Section 15 (d) and Section 17 from the requirements of
14 subsection (c) of this Section when such requirements are not
15 necessary for the protection of the public health.
16     (f) A drug which is subject to subsection (c) of this
17 Section shall be deemed to be misbranded if at any time before
18 dispensing its label fails to bear the statement "Caution:
19 Federal Law Prohibits Dispensing Without Prescription" or
20 "Caution: State Law Prohibits Dispensing Without
21 Prescription". A drug to which subsection (c) of this Section
22 does not apply shall be deemed to be misbranded if at any time
23 prior to dispensing its label bears the caution statement
24 quoted in the preceding sentence.
25     (g) Nothing in this Section shall be construed to relieve
26 any person from any requirement prescribed by or under

 

 

HB0813 Engrossed - 17 - LRB095 09713 DRJ 29917 b

1 authority of law with respect to controlled substances now
2 included or which may hereafter be included within the
3 classifications of controlled substances cannabis as defined
4 in applicable Federal laws relating to controlled substances or
5 cannabis or the Cannabis Control Act.
6 (Source: P.A. 84-1308.)
 
7     Section 94. The Illinois Controlled Substances Act is
8 amended by changing Section 102 as follows:
 
9     (720 ILCS 570/102)  (from Ch. 56 1/2, par. 1102)
10     Sec. 102. Definitions. As used in this Act, unless the
11 context otherwise requires:
12     (a) "Addict" means any person who habitually uses any drug,
13 chemical, substance or dangerous drug other than alcohol so as
14 to endanger the public morals, health, safety or welfare or who
15 is so far addicted to the use of a dangerous drug or controlled
16 substance other than alcohol as to have lost the power of self
17 control with reference to his addiction.
18     (b) "Administer" means the direct application of a
19 controlled substance, whether by injection, inhalation,
20 ingestion, or any other means, to the body of a patient,
21 research subject, or animal (as defined by the Humane
22 Euthanasia in Animal Shelters Act) by:
23         (1) a practitioner (or, in his presence, by his
24     authorized agent),

 

 

HB0813 Engrossed - 18 - LRB095 09713 DRJ 29917 b

1         (2) the patient or research subject at the lawful
2     direction of the practitioner, or
3         (3) a euthanasia technician as defined by the Humane
4     Euthanasia in Animal Shelters Act.
5     (c) "Agent" means an authorized person who acts on behalf
6 of or at the direction of a manufacturer, distributor, or
7 dispenser. It does not include a common or contract carrier,
8 public warehouseman or employee of the carrier or warehouseman.
9     (c-1) "Anabolic Steroids" means any drug or hormonal
10 substance, chemically and pharmacologically related to
11 testosterone (other than estrogens, progestins, and
12 corticosteroids) that promotes muscle growth, and includes:
13             (i) boldenone,
14             (ii) chlorotestosterone,
15             (iii) chostebol,
16             (iv) dehydrochlormethyltestosterone,
17             (v) dihydrotestosterone,
18             (vi) drostanolone,
19             (vii) ethylestrenol,
20             (viii) fluoxymesterone,
21             (ix) formebulone,
22             (x) mesterolone,
23             (xi) methandienone,
24             (xii) methandranone,
25             (xiii) methandriol,
26             (xiv) methandrostenolone,

 

 

HB0813 Engrossed - 19 - LRB095 09713 DRJ 29917 b

1             (xv) methenolone,
2             (xvi) methyltestosterone,
3             (xvii) mibolerone,
4             (xviii) nandrolone,
5             (xix) norethandrolone,
6             (xx) oxandrolone,
7             (xxi) oxymesterone,
8             (xxii) oxymetholone,
9             (xxiii) stanolone,
10             (xxiv) stanozolol,
11             (xxv) testolactone,
12             (xxvi) testosterone,
13             (xxvii) trenbolone, and
14             (xxviii) any salt, ester, or isomer of a drug or
15         substance described or listed in this paragraph, if
16         that salt, ester, or isomer promotes muscle growth.
17     Any person who is otherwise lawfully in possession of an
18 anabolic steroid, or who otherwise lawfully manufactures,
19 distributes, dispenses, delivers, or possesses with intent to
20 deliver an anabolic steroid, which anabolic steroid is
21 expressly intended for and lawfully allowed to be administered
22 through implants to livestock or other nonhuman species, and
23 which is approved by the Secretary of Health and Human Services
24 for such administration, and which the person intends to
25 administer or have administered through such implants, shall
26 not be considered to be in unauthorized possession or to

 

 

HB0813 Engrossed - 20 - LRB095 09713 DRJ 29917 b

1 unlawfully manufacture, distribute, dispense, deliver, or
2 possess with intent to deliver such anabolic steroid for
3 purposes of this Act.
4     (d) "Administration" means the Drug Enforcement
5 Administration, United States Department of Justice, or its
6 successor agency.
7     (e) "Control" means to add a drug or other substance, or
8 immediate precursor, to a Schedule under Article II of this Act
9 whether by transfer from another Schedule or otherwise.
10     (f) "Controlled Substance" means a drug, substance, or
11 immediate precursor in the Schedules of Article II of this Act.
12     (g) "Counterfeit substance" means a controlled substance,
13 which, or the container or labeling of which, without
14 authorization bears the trademark, trade name, or other
15 identifying mark, imprint, number or device, or any likeness
16 thereof, of a manufacturer, distributor, or dispenser other
17 than the person who in fact manufactured, distributed, or
18 dispensed the substance.
19     (h) "Deliver" or "delivery" means the actual, constructive
20 or attempted transfer of possession of a controlled substance,
21 with or without consideration, whether or not there is an
22 agency relationship. The term does not include the donation of
23 prescription drugs to the extent permitted under the Cancer
24 Drug Repository Program Act.
25     (i) "Department" means the Illinois Department of Human
26 Services (as successor to the Department of Alcoholism and

 

 

HB0813 Engrossed - 21 - LRB095 09713 DRJ 29917 b

1 Substance Abuse) or its successor agency.
2     (j) "Department of State Police" means the Department of
3 State Police of the State of Illinois or its successor agency.
4     (k) "Department of Corrections" means the Department of
5 Corrections of the State of Illinois or its successor agency.
6     (l) "Department of Professional Regulation" means the
7 Department of Professional Regulation of the State of Illinois
8 or its successor agency.
9     (m) "Depressant" or "stimulant substance" means:
10         (1) a drug which contains any quantity of (i)
11     barbituric acid or any of the salts of barbituric acid
12     which has been designated as habit forming under section
13     502 (d) of the Federal Food, Drug, and Cosmetic Act (21
14     U.S.C. 352 (d)); or
15         (2) a drug which contains any quantity of (i)
16     amphetamine or methamphetamine and any of their optical
17     isomers; (ii) any salt of amphetamine or methamphetamine or
18     any salt of an optical isomer of amphetamine; or (iii) any
19     substance which the Department, after investigation, has
20     found to be, and by rule designated as, habit forming
21     because of its depressant or stimulant effect on the
22     central nervous system; or
23         (3) lysergic acid diethylamide; or
24         (4) any drug which contains any quantity of a substance
25     which the Department, after investigation, has found to
26     have, and by rule designated as having, a potential for

 

 

HB0813 Engrossed - 22 - LRB095 09713 DRJ 29917 b

1     abuse because of its depressant or stimulant effect on the
2     central nervous system or its hallucinogenic effect.
3     (n) (Blank).
4     (o) "Director" means the Director of the Department of
5 State Police or the Department of Professional Regulation or
6 his designated agents.
7     (p) "Dispense" means to deliver a controlled substance to
8 an ultimate user or research subject by or pursuant to the
9 lawful order of a prescriber, including the prescribing,
10 administering, packaging, labeling, or compounding necessary
11 to prepare the substance for that delivery.
12     (q) "Dispenser" means a practitioner who dispenses.
13     (r) "Distribute" means to deliver, other than by
14 administering or dispensing, a controlled substance.
15     (s) "Distributor" means a person who distributes.
16     (t) "Drug" means (1) substances recognized as drugs in the
17 official United States Pharmacopoeia, Official Homeopathic
18 Pharmacopoeia of the United States, or official National
19 Formulary, or any supplement to any of them; (2) substances
20 intended for use in diagnosis, cure, mitigation, treatment, or
21 prevention of disease in man or animals; (3) substances (other
22 than food) intended to affect the structure of any function of
23 the body of man or animals and (4) substances intended for use
24 as a component of any article specified in clause (1), (2), or
25 (3) of this subsection. It does not include devices or their
26 components, parts, or accessories.

 

 

HB0813 Engrossed - 23 - LRB095 09713 DRJ 29917 b

1     (t-5) "Euthanasia agency" means an entity certified by the
2 Department of Professional Regulation for the purpose of animal
3 euthanasia that holds an animal control facility license or
4 animal shelter license under the Animal Welfare Act. A
5 euthanasia agency is authorized to purchase, store, possess,
6 and utilize Schedule II nonnarcotic and Schedule III
7 nonnarcotic drugs for the sole purpose of animal euthanasia.
8     (t-10) "Euthanasia drugs" means Schedule II or Schedule III
9 substances (nonnarcotic controlled substances) that are used
10 by a euthanasia agency for the purpose of animal euthanasia.
11     (u) "Good faith" means the prescribing or dispensing of a
12 controlled substance by a practitioner in the regular course of
13 professional treatment to or for any person who is under his
14 treatment for a pathology or condition other than that
15 individual's physical or psychological dependence upon or
16 addiction to a controlled substance, except as provided herein:
17 and application of the term to a pharmacist shall mean the
18 dispensing of a controlled substance pursuant to the
19 prescriber's order which in the professional judgment of the
20 pharmacist is lawful. The pharmacist shall be guided by
21 accepted professional standards including, but not limited to
22 the following, in making the judgment:
23         (1) lack of consistency of doctor-patient
24     relationship,
25         (2) frequency of prescriptions for same drug by one
26     prescriber for large numbers of patients,

 

 

HB0813 Engrossed - 24 - LRB095 09713 DRJ 29917 b

1         (3) quantities beyond those normally prescribed,
2         (4) unusual dosages,
3         (5) unusual geographic distances between patient,
4     pharmacist and prescriber,
5         (6) consistent prescribing of habit-forming drugs.
6     (u-1) "Home infusion services" means services provided by a
7 pharmacy in compounding solutions for direct administration to
8 a patient in a private residence, long-term care facility, or
9 hospice setting by means of parenteral, intravenous,
10 intramuscular, subcutaneous, or intraspinal infusion.
11     (v) "Immediate precursor" means a substance:
12         (1) which the Department has found to be and by rule
13     designated as being a principal compound used, or produced
14     primarily for use, in the manufacture of a controlled
15     substance;
16         (2) which is an immediate chemical intermediary used or
17     likely to be used in the manufacture of such controlled
18     substance; and
19         (3) the control of which is necessary to prevent,
20     curtail or limit the manufacture of such controlled
21     substance.
22     (w) "Instructional activities" means the acts of teaching,
23 educating or instructing by practitioners using controlled
24 substances within educational facilities approved by the State
25 Board of Education or its successor agency.
26     (x) "Local authorities" means a duly organized State,

 

 

HB0813 Engrossed - 25 - LRB095 09713 DRJ 29917 b

1 County or Municipal peace unit or police force.
2     (y) "Look-alike substance" means a substance, other than a
3 controlled substance which (1) by overall dosage unit
4 appearance, including shape, color, size, markings or lack
5 thereof, taste, consistency, or any other identifying physical
6 characteristic of the substance, would lead a reasonable person
7 to believe that the substance is a controlled substance, or (2)
8 is expressly or impliedly represented to be a controlled
9 substance or is distributed under circumstances which would
10 lead a reasonable person to believe that the substance is a
11 controlled substance. For the purpose of determining whether
12 the representations made or the circumstances of the
13 distribution would lead a reasonable person to believe the
14 substance to be a controlled substance under this clause (2) of
15 subsection (y), the court or other authority may consider the
16 following factors in addition to any other factor that may be
17 relevant:
18         (a) statements made by the owner or person in control
19     of the substance concerning its nature, use or effect;
20         (b) statements made to the buyer or recipient that the
21     substance may be resold for profit;
22         (c) whether the substance is packaged in a manner
23     normally used for the illegal distribution of controlled
24     substances;
25         (d) whether the distribution or attempted distribution
26     included an exchange of or demand for money or other

 

 

HB0813 Engrossed - 26 - LRB095 09713 DRJ 29917 b

1     property as consideration, and whether the amount of the
2     consideration was substantially greater than the
3     reasonable retail market value of the substance.
4     Clause (1) of this subsection (y) shall not apply to a
5 noncontrolled substance in its finished dosage form that was
6 initially introduced into commerce prior to the initial
7 introduction into commerce of a controlled substance in its
8 finished dosage form which it may substantially resemble.
9     Nothing in this subsection (y) prohibits the dispensing or
10 distributing of noncontrolled substances by persons authorized
11 to dispense and distribute controlled substances under this
12 Act, provided that such action would be deemed to be carried
13 out in good faith under subsection (u) if the substances
14 involved were controlled substances.
15     Nothing in this subsection (y) or in this Act prohibits the
16 manufacture, preparation, propagation, compounding,
17 processing, packaging, advertising or distribution of a drug or
18 drugs by any person registered pursuant to Section 510 of the
19 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).
20     (y-1) "Mail-order pharmacy" means a pharmacy that is
21 located in a state of the United States, other than Illinois,
22 that delivers, dispenses or distributes, through the United
23 States Postal Service or other common carrier, to Illinois
24 residents, any substance which requires a prescription.
25     (z) "Manufacture" means the production, preparation,
26 propagation, compounding, conversion or processing of a

 

 

HB0813 Engrossed - 27 - LRB095 09713 DRJ 29917 b

1 controlled substance other than methamphetamine, either
2 directly or indirectly, by extraction from substances of
3 natural origin, or independently by means of chemical
4 synthesis, or by a combination of extraction and chemical
5 synthesis, and includes any packaging or repackaging of the
6 substance or labeling of its container, except that this term
7 does not include:
8         (1) by an ultimate user, the preparation or compounding
9     of a controlled substance for his own use; or
10         (2) by a practitioner, or his authorized agent under
11     his supervision, the preparation, compounding, packaging,
12     or labeling of a controlled substance:
13             (a) as an incident to his administering or
14         dispensing of a controlled substance in the course of
15         his professional practice; or
16             (b) as an incident to lawful research, teaching or
17         chemical analysis and not for sale; or .
18         (3) the packaging, repackaging, or labeling of
19     prescription drugs only to the extent required under the
20     Cancer Drug Repository Program Act.
21     (z-1) (Blank).
22     (aa) "Narcotic drug" means any of the following, whether
23 produced directly or indirectly by extraction from substances
24 of natural origin, or independently by means of chemical
25 synthesis, or by a combination of extraction and chemical
26 synthesis:

 

 

HB0813 Engrossed - 28 - LRB095 09713 DRJ 29917 b

1         (1) opium and opiate, and any salt, compound,
2     derivative, or preparation of opium or opiate;
3         (2) any salt, compound, isomer, derivative, or
4     preparation thereof which is chemically equivalent or
5     identical with any of the substances referred to in clause
6     (1), but not including the isoquinoline alkaloids of opium;
7         (3) opium poppy and poppy straw;
8         (4) coca leaves and any salts, compound, isomer, salt
9     of an isomer, derivative, or preparation of coca leaves
10     including cocaine or ecgonine, and any salt, compound,
11     isomer, derivative, or preparation thereof which is
12     chemically equivalent or identical with any of these
13     substances, but not including decocainized coca leaves or
14     extractions of coca leaves which do not contain cocaine or
15     ecgonine (for the purpose of this paragraph, the term
16     "isomer" includes optical, positional and geometric
17     isomers).
18     (bb) "Nurse" means a registered nurse licensed under the
19 Nursing and Advanced Practice Nursing Act.
20     (cc) (Blank).
21     (dd) "Opiate" means any substance having an addiction
22 forming or addiction sustaining liability similar to morphine
23 or being capable of conversion into a drug having addiction
24 forming or addiction sustaining liability.
25     (ee) "Opium poppy" means the plant of the species Papaver
26 somniferum L., except its seeds.

 

 

HB0813 Engrossed - 29 - LRB095 09713 DRJ 29917 b

1     (ff) "Parole and Pardon Board" means the Parole and Pardon
2 Board of the State of Illinois or its successor agency.
3     (gg) "Person" means any individual, corporation,
4 mail-order pharmacy, government or governmental subdivision or
5 agency, business trust, estate, trust, partnership or
6 association, or any other entity.
7     (hh) "Pharmacist" means any person who holds a certificate
8 of registration as a registered pharmacist, a local registered
9 pharmacist or a registered assistant pharmacist under the
10 Pharmacy Practice Act of 1987.
11     (ii) "Pharmacy" means any store, ship or other place in
12 which pharmacy is authorized to be practiced under the Pharmacy
13 Practice Act of 1987.
14     (jj) "Poppy straw" means all parts, except the seeds, of
15 the opium poppy, after mowing.
16     (kk) "Practitioner" means a physician licensed to practice
17 medicine in all its branches, dentist, podiatrist,
18 veterinarian, scientific investigator, pharmacist, physician
19 assistant, advanced practice nurse, licensed practical nurse,
20 registered nurse, hospital, laboratory, or pharmacy, or other
21 person licensed, registered, or otherwise lawfully permitted
22 by the United States or this State to distribute, dispense,
23 conduct research with respect to, administer or use in teaching
24 or chemical analysis, a controlled substance in the course of
25 professional practice or research.
26     (ll) "Pre-printed prescription" means a written

 

 

HB0813 Engrossed - 30 - LRB095 09713 DRJ 29917 b

1 prescription upon which the designated drug has been indicated
2 prior to the time of issuance.
3     (mm) "Prescriber" means a physician licensed to practice
4 medicine in all its branches, dentist, podiatrist or
5 veterinarian who issues a prescription, a physician assistant
6 who issues a prescription for a Schedule III, IV, or V
7 controlled substance in accordance with Section 303.05 and the
8 written guidelines required under Section 7.5 of the Physician
9 Assistant Practice Act of 1987, or an advanced practice nurse
10 with prescriptive authority in accordance with Section 303.05
11 and a written collaborative agreement under Sections 15-15 and
12 15-20 of the Nursing and Advanced Practice Nursing Act.
13     (nn) "Prescription" means a lawful written, facsimile, or
14 verbal order of a physician licensed to practice medicine in
15 all its branches, dentist, podiatrist or veterinarian for any
16 controlled substance, of a physician assistant for a Schedule
17 III, IV, or V controlled substance in accordance with Section
18 303.05 and the written guidelines required under Section 7.5 of
19 the Physician Assistant Practice Act of 1987, or of an advanced
20 practice nurse who issues a prescription for a Schedule III,
21 IV, or V controlled substance in accordance with Section 303.05
22 and a written collaborative agreement under Sections 15-15 and
23 15-20 of the Nursing and Advanced Practice Nursing Act.
24     (oo) "Production" or "produce" means manufacture,
25 planting, cultivating, growing, or harvesting of a controlled
26 substance other than methamphetamine.

 

 

HB0813 Engrossed - 31 - LRB095 09713 DRJ 29917 b

1     (pp) "Registrant" means every person who is required to
2 register under Section 302 of this Act.
3     (qq) "Registry number" means the number assigned to each
4 person authorized to handle controlled substances under the
5 laws of the United States and of this State.
6     (rr) "State" includes the State of Illinois and any state,
7 district, commonwealth, territory, insular possession thereof,
8 and any area subject to the legal authority of the United
9 States of America.
10     (ss) "Ultimate user" means a person who lawfully possesses
11 a controlled substance for his own use or for the use of a
12 member of his household or for administering to an animal owned
13 by him or by a member of his household.
14 (Source: P.A. 93-596, eff. 8-26-03; 93-626, eff. 12-23-03;
15 94-556, eff. 9-11-05.)
 
16     Section 95. The Cannabis and Controlled Substances Tort
17 Claims Act is amended by changing Section 3 as follows:
 
18     (740 ILCS 20/3)  (from Ch. 70, par. 903)
19     Sec. 3. Definitions. As used in this Act, unless the
20 context otherwise requires:
21     "Cannabis" includes marihuana, hashish, and other
22 substances that are identified as including any parts of the
23 plant Cannabis Sativa, whether growing or not, the seeds of
24 that plant, the resin extracted from any part of that plant,

 

 

HB0813 Engrossed - 32 - LRB095 09713 DRJ 29917 b

1 and any compound, manufacture, salt, derivative, mixture, or
2 preparation of that plant, its seeds, or resin, including
3 tetrahydrocannabinol (THC) and all other cannabinol
4 derivatives, including its naturally occurring or
5 synthetically produced ingredients, whether produced directly
6 or indirectly by extraction, independently by means of chemical
7 synthesis, or by a combination of extraction and chemical
8 synthesis. "Cannabis" does not include the mature stalks of
9 that plant, fiber produced from those stalks, oil or cake made
10 from the seeds of that plant, any other compound, manufacture,
11 salt, derivative, mixture, or preparation of mature stalks
12 (except the extracted resin), fiber, oil or cake, or the
13 sterilized seeds of that plant that are incapable of
14 germination.
15     "Controlled substance" means a drug, substance, or
16 immediate precursor in the Schedules of Article II of the
17 Illinois Controlled Substances Act.
18     "Counterfeit substance" means a controlled substance or
19 the container or labeling of a controlled substance that,
20 without authorization, bears the trademark, trade name, or
21 other identifying mark, imprint, number, device, or any
22 likeness thereof of a manufacturer, distributor, or dispenser
23 other than the person who in fact manufactured, distributed, or
24 dispensed the substance.
25     "Deliver" or "delivery" means the actual, constructive, or
26 attempted transfer of possession of a controlled substance or

 

 

HB0813 Engrossed - 33 - LRB095 09713 DRJ 29917 b

1 cannabis, with or without consideration, whether or not there
2 is an agency relationship. The term does not include the
3 donation of prescription drugs to the extent permitted under
4 the Cancer Drug Repository Program Act.
5     "Manufacture" means the production, preparation,
6 propagation, compounding, conversion, or processing of a
7 controlled substance, either directly or indirectly, by
8 extraction from substances of natural origin, independently by
9 means of chemical synthesis, or by a combination of extraction
10 and chemical synthesis, and includes any packaging or
11 repackaging of the substance or labeling of its container,
12 except that the term does not include:
13         (1) by an ultimate user, the preparation or compounding
14     of a controlled substance for his own use;
15         (2) by a practitioner or his authorized agent under his
16     supervision, the preparation, compounding, packaging, or
17     labeling of a controlled substance: ;
18             (A) as an incident to his administering or
19         dispensing of a controlled substance in the course of
20         his professional practice; or
21             (B) as an incident to lawful research, teaching or
22         chemical analysis and not for sale; or
23         (3) the preparation, compounding, packaging, or
24     labeling of cannabis as an incident to lawful research,
25     teaching, or chemical analysis and not for sale; or .
26         (4) the packaging, repackaging, or labeling of

 

 

HB0813 Engrossed - 34 - LRB095 09713 DRJ 29917 b

1     prescription drugs only to the extent required under the
2     Cancer Drug Repository Program Act.
3     "Owner" means a person who has possession of or any
4 interest whatsoever in the property involved.
5     "Person" means an individual, a corporation, a government,
6 a governmental subdivision or agency, a business trust, an
7 estate, a trust, a partnership or association, or any other
8 entity.
9     "Production" means planting, cultivating, tending, or
10 harvesting.
11     "Property" means real property, including things growing
12 on, affixed to, and found in land, and tangible or intangible
13 personal property, including rights, services, privileges,
14 interests, claims, and securities.
15 (Source: P.A. 87-544.)

 

 

HB0813 Engrossed - 35 - LRB095 09713 DRJ 29917 b

1 INDEX
2 Statutes amended in order of appearance
3     New Act
4     225 ILCS 85/4 from Ch. 111, par. 4124
5     225 ILCS 120/15 from Ch. 111, par. 8301-15
6     320 ILCS 50/10
7     410 ILCS 620/16 from Ch. 56 1/2, par. 516
8     720 ILCS 570/102 from Ch. 56 1/2, par. 1102
9     740 ILCS 20/3 from Ch. 70, par. 903